Daiichi Sankyo to Promote Osteoporosis Treatment Pralia with Focus on Appropriate Use

Ryoichi Kibushi, Head of Sales & Marketing Division Daiichi Sankyo will focus on providing information on the appropriate use of its newly launched osteoporosis treatment Pralia (recombinant denosumab) during its promotion, the company said on July 3 at a press...read more